Brief: LIXTE Biotechnology And The Spanish Sarcoma Group Enroll First Patient In A Phase 1B/2 Randomized Trial Of Doxorubicin +/- Lixte’S Lead Anti-Cancer Compound, Lb-100, In Advanced Soft Tissue Sarcomas

NOMAD Power Solutions

07/06/2023 14:11

June 7 (Reuters) - Lixte Biotechnology Holdings Inc
 LIXT.O :
    * LIXTE BIOTECHNOLOGY AND THE SPANISH SARCOMA GROUP ENROLL
FIRST
PATIENT IN A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-
LIXTE’S LEAD ANTI-CANCER COMPOUND, LB-100, IN ADVANCED SOFT
TISSUE SARCOMAS

Source text for Eikon:  ID:nGNXk6VRZ 
Further company coverage:  LIXT.O 

 ((Reuters.Briefs@thomsonreuters.com;))